De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Black Diamond Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Black Diamond Therapeutics' is Mark Velleca, benoemd in Sep2023, heeft een ambtstermijn van 1.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.39M, bestaande uit 5.3% salaris en 94.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.082% van de aandelen van het bedrijf, ter waarde $ 202.36K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 4.3 jaar.

Belangrijke informatie

Mark Velleca

Algemeen directeur

US$3.4m

Totale compensatie

Percentage CEO-salaris	5.3%
Dienstverband CEO	1.1yrs
Eigendom CEO	0.08%
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	4.3yrs

Recente managementupdates

Recent updates

Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive

Jun 27

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

May 21

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Jan 31

Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM

Jan 12

Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation

Oct 26

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

May 05

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Jan 16

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?

Oct 02

Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?

Jul 02

We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully

Jan 16

We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely

Jun 11

Black Diamond Therapeutics EPS misses by $0.16

May 07

We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Feb 26

What You Need To Know About Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Investor Composition

Jan 05

Have Insiders Been Buying Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares?

Dec 01

Analyse CEO-vergoeding

Hoe is Mark Velleca's beloning veranderd ten opzichte van Black Diamond Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$81m
Mar 31 2024	n/a	n/a	-US$80m
Dec 31 2023	US$3m	US$180k	-US$82m
Sep 30 2023	n/a	n/a	-US$84m
Jun 30 2023	n/a	n/a	-US$83m
Mar 31 2023	n/a	n/a	-US$87m
Dec 31 2022	US$65k	n/a	-US$91m
Sep 30 2022	n/a	n/a	-US$96m
Jun 30 2022	n/a	n/a	-US$109m
Mar 31 2022	n/a	n/a	-US$121m
Dec 31 2021	US$204k	n/a	-US$126m

Compensatie versus markt: De totale vergoeding ($USD 3.39M ) Mark } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.49M ).

Compensatie versus inkomsten: De vergoeding van Mark is gestegen terwijl het bedrijf verliesgevend is.

CEO

Mark Velleca (60 yo)

1.1yrs

Tenure

US$3,387,383

Compensatie

Dr. Mark A. Velleca, M. D., Ph. D., serves as President & Chief Executive Officer at Black Diamond Therapeutics, Inc. since September 16, 2023 and serves as its Chairman since December 2022. He has been an...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Mark Velleca	CEO, President & Chairman	1.1yrs	US$3.39m	0.082% $ 174.5k
David M. Epstein	Co-Founder & Director	no data	US$2.02m	1.62% $ 3.4m
Fang Ni	CFO, Principal Financial Officer and Chief Business Officer	2.9yrs	US$1.49m	0.23% $ 481.2k
Sergey Yurasov	Chief Medical Officer	2.3yrs	US$1.23m	0% $ 0
Elizabeth Buck	Co-Founder & Chief Scientific Officer	3.2yrs	US$347.30k	geen gegevens
Brent Hatzis-Schoch	COO & General Counsel	5.4yrs	US$911.23k	0.015% $ 31.5k
Elizabeth Montgomery	Chief People Officer	2.7yrs	geen gegevens	geen gegevens
Melanie Morrison	Chief Development Officer	1.9yrs	geen gegevens	geen gegevens
Erika Jones	Senior VP of Finance & Corporate Controller	3.8yrs	geen gegevens	0.0054% $ 11.4k

2.8yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BDTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Mark Velleca	CEO, President & Chairman	3.2yrs	US$3.39m	0.082% $ 174.5k
David M. Epstein	Co-Founder & Director	8.1yrs	US$2.02m	1.62% $ 3.4m
Ali Behbahani	Independent Director	5.8yrs	US$68.14k	0.10% $ 215.9k
Garry Menzel	Independent Director	7.6yrs	US$75.35k	0.14% $ 287.5k
Kapil Dhingra	Independent Director	3.8yrs	US$109.35k	0.018% $ 37.5k
Samarth Kulkarni	Lead Independent Director	4.9yrs	US$59.35k	0% $ 0
Prakash Raman	Independent Director	less than a year	geen gegevens	0.0088% $ 18.7k
Shannon Campbell	Independent Director	less than a year	geen gegevens	0.0077% $ 16.4k

4.3yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BDTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Black Diamond Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Co-Founder & Director notifies of intention to sell stock

Black Diamond Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Black Diamond Therapeutics, Inc. Announces Resignation of Rajeev Shah from Board of Directors, Including as A Member of the Audit Committee of the Board

Black Diamond Therapeutics, Inc. Announces Chief Executive Officer Changes

Key Executive recently bought US$72k worth of stock

Black Diamond Therapeutics, Inc. Announces Changes to Board of Directors

Recent updates

Black Diamond Therapeutics, Inc. Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients

Price target increased by 8.1% to US$13.83

Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive

Co-Founder & Director notifies of intention to sell stock

New major risk - Shareholder dilution

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

Black Diamond Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Price target increased by 9.4% to US$11.60

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Black Diamond Therapeutics, Inc. Announces Resignation of Rajeev Shah from Board of Directors, Including as A Member of the Audit Committee of the Board

Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM

Black Diamond Therapeutics, Inc. Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

New minor risk - Share price stability

Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation

New minor risk - Market cap size

Black Diamond Therapeutics, Inc. Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Black Diamond Therapeutics, Inc. Announces Chief Executive Officer Changes

Black Diamond Therapeutics, Inc. Doses First Patients in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer

New major risk - Financial position

New minor risk - Shareholder dilution

New major risk - Share price stability

Black Diamond Therapeutics, Inc. Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families

Price target increased by 38% to US$9.33

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Key Executive recently bought US$72k worth of stock

Black Diamond Therapeutics, Inc. Announces Changes to Board of Directors

High number of new directors

Black Diamond Therapeutics, Inc. Appoints as Melanie Morrison as Senior Vice President, Development Operations

Black Diamond Therapeutics, Inc. Presents Preclinical Data on BDTX-1535 and BDTX-4933 at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?

Price target decreased to US$7.00

Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?

Key Executive recently bought US$61k worth of stock

Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) dropped from Russell 2500 Index

Black Diamond Therapeutics Appoints Sergey Yurasov as Chief Medical Officer

High number of new directors

Black Diamond Therapeutics Announces Publication of New Computational and Functional Analyses of HER2 Mutations Based on its Proprietary MAP Discovery Engine

Price target decreased to US$8.00

High number of new directors

Black Diamond Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Study of BDTX-1535

Black Diamond Therapeutics, Inc. Announces Board Changes

Price target decreased to US$21.60

Black Diamond Therapeutics Appoints Elizabeth Montgomery as Chief People Officer

We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully

Black Diamond Therapeutics Announces FDA Allowance of IND Application for BDTX-1535, a MasterKey Inhibitor of EGFR for the Treatment of Gliobastoma and Non-Small Cell Lung Cancer

Executive Officer Thomas Leggett has left the company

Price target decreased to US$42.83

Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) dropped from Russell 2500 Growth Index

We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely

Black Diamond Therapeutics, Inc. Presents Phase 1 Pharmacokinetic, Safety, and Preliminary Efficacy Data of BDTX-189 in Advanced Solid Tumors Harboring EGFR or HER2 Alterations

COO & General Counsel exercised options and sold US$99k worth of stock

Black Diamond Therapeutics EPS misses by $0.16

COO & General Counsel exercised options and sold US$89k worth of stock

COO & General Counsel exercised options and sold US$94k worth of stock

Chief Scientific Officer notifies of intention to sell stock

Black Diamond Therapeutics Announces Pre-Clinical Data Presentations on New Programs Targeting BRAF and FGFR at ESMO TAT Virtual Congress 2021

We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

COO & General Counsel exercised options and sold US$98k worth of stock

Diamond Therapeutics Signs Agreement with McGill University for Research on Low-Dose LSD

Black Diamond Therapeutics, Inc. Appoints Kapil Dhingra to Board of Directors

New 90-day low: US$28.62

What You Need To Know About Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Investor Composition

Co-Founder notifies of intention to sell stock

Have Insiders Been Buying Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares?

Black Diamond Therapeutics, Inc. Provides Update on Gbm Program and Presents Pre-Clinical Data At the 2020 Sno Annual Meeting

Black Diamond nominates development candidate for glioblastoma program

Chief Financial Officer exercised options and sold US$66k worth of stock

Black Diamond Therapeutics Provides Corporate Update